Streetbeat News

NKGN

NKGen Biotech, Inc. Common Stock

https://www.grafacq.com

Industry

Biotechnology

Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

NKGen Biotech has received a non-compliance notification from Nasdaq due to a delay in filing its quarterly report. This could impact the company's stock price and investor confidence.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 8:42 pm

NKGen Biotech presented new data on their SNK01 product at the 2024 AAIC, showing it can reduce α-synuclein levels in Alzheimer's patients' CSF and improve cognitive function. This is significant as increased α-synuclein is linked to worse cognitive performance and is not targeted by current treatments.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 12:17 pm

Shares of Tellurian Inc. (NASDAQ:TELL) surged 65% in pre-market trading after Woodside Energy announced plans to acquire the company for $900 million in an all-cash deal. Other notable pre-market movers include Netcapital Inc. (NASDAQ:NCPL), Serve Robotics Inc. (NASDAQ:SERV), and Ryanair Holdings plc (NASDAQ:RYAAY).

Portfolio Pulse from Avi Kapoor

July 22, 2024 | 9:24 am

Domino's Pizza shares fell over 11% after reporting mixed quarterly results, missing sales estimates and suspending its guidance on global net store growth. Other notable stock movements include significant gains for Onconetix, Silo Pharma, and Chuy's Holdings, and sharp declines for Agenus, Leslie's, and Alaunos Therapeutics.

Portfolio Pulse from Avi Kapoor

July 18, 2024 | 5:19 pm

NKGen Biotech Inc (NASDAQ:NKGN) shares surged by 25% to $1.17 after announcing the presentation of new SNK01 biomarker data at the Alzheimer’s Association International Conference. The data shows SNK01’s potential in reducing α-synuclein, linked to cognitive decline in Alzheimer’s patients. The presentation will be held on July 30, 2024, with additional details available on NKGen’s website.

Portfolio Pulse from Henry Khederian

July 18, 2024 | 3:06 pm

Market-Moving News for July 18th includes significant updates for NKGen Biotech, Agenus, and Beyond Meat. NKGen Biotech will present new biomarker data on SNK01 in Alzheimer's Disease at an upcoming conference. Agenus shares dropped after the FDA discouraged an accelerated approval pathway. Beyond Meat shares fell due to concerns over weakened liquidity and debt discussions.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:28 pm

NKGen Biotech shares are trading higher following the announcement that the company will present new SNK01 biomarker data at the Alzheimer's Association International Conference.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:23 pm

NKGen Biotech will present new biomarker data on SNK01, an autologous non-genetically modified NK cell therapy, at the Alzheimer's Association International Conference. The data will focus on SNK01's ability to reduce α-synuclein in Alzheimer's patients, which is linked to cognitive function.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2024 | 12:13 pm

NKGen Biotech has presented a novel manufacturing and cryopreservation process for its allogeneic NK cell therapy, SNK02. CEO Dr. Paul Y. Song provided updates on the initial Phase 1 results for treating advanced refractory solid tumors.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 5:07 pm

NKGen Biotech will present updated Phase 1 data of its SNK02 allogeneic NK cell therapy in solid tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:26 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.